Overview: Mixtard-30 100 IU/mL is a suspension for injection containing human insulin (insulin isophane) as its active substance. It is manufactured by Novo Nordisk, a leading pharmaceutical company known for its expertise in diabetes care.
Active Substance: Human Insulin (Insulin Isophane) is a type of intermediate-acting insulin that helps control blood sugar levels in patients with diabetes mellitus. Insulin isophane is characterized by its extended duration of action compared to regular insulin, making it suitable for maintaining basal insulin levels throughout the day.
Indications: Mixtard-30 100 IU/mL is indicated for the treatment of diabetes mellitus in adults, adolescents, and children above the age of 2 years. It helps in the management of both type 1 and type 2 diabetes by regulating glucose metabolism.
Mechanism of Action: Insulin isophane works by facilitating the uptake of glucose into cells, where it is used for energy production or stored as glycogen. This action helps to lower blood glucose levels and prevents hyperglycemia.
Dosage and Administration: The dosage of Mixtard-30 100 IU/mL varies depending on individual patient requirements, including age, weight, and severity of diabetes. It is administered subcutaneously using a syringe or an insulin pen. Dosage adjustments may be necessary based on blood glucose monitoring and under medical supervision.
Storage: Store Mixtard-30 cartridges in a refrigerator (2°C – 8°C). Do not freeze. Once in use, cartridges should be kept at room temperature (below 30°C) for up to 6 weeks. Protect from light and heat.
Precautions and Warnings:
- Patients should be educated on proper injection techniques and blood glucose monitoring.
- Hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) may occur; patients should be aware of symptoms and how to manage them.
- Use with caution in patients with renal or hepatic impairment and during pregnancy or breastfeeding.
- Regular medical follow-up is essential to adjust dosage and monitor treatment efficacy.
Adverse Reactions: Common side effects may include injection site reactions (e.g., redness, swelling), hypoglycemia, allergic reactions, and lipodystrophy at injection sites. Serious adverse reactions are rare but may include severe hypoglycemia or allergic reactions.
Contraindications: Mixtard-30 100 IU/mL is contraindicated in patients with hypersensitivity to insulin isophane or any components of the formulation. It should not be used during episodes of hypoglycemia or in insulin pumps.
Conclusion: Mixtard-30 100 IU/mL by Novo Nordisk is a trusted choice for managing diabetes mellitus, providing reliable control of blood glucose levels through its sustained-release formulation of human insulin isophane. With careful dosage adjustments and proper patient education, it contributes significantly to improving the quality of life for patients living with diabetes.
Always consult healthcare professionals for personalized guidance regarding the use of Mixtard-30 100 IU/mL based on individual medical needs and conditions.
Reviews
There are no reviews yet.